SpringWorks Therapeutics, Inc. SWTX
Set alert
At close · Jul 1
52-week range unavailable
- Open
- 46.99
- Prev close
- 46.99
- Mkt cap
- 3.54B
- Vol
- 5.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 46.99
- High
- 46.99
- Forward P/E
- -21.96
- Beta
- 0.70
- Short ratio
- 1.46
- Inst. own
- 87.40%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 46.50
- 200-d avg
- 41.63
- 1y target
- 47.00
News
1 year ago globenewswire.com
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and…
1 year ago globenewswire.com
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and…
1 year ago globenewswire.com
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the…
1 year ago globenewswire.com
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the…
1 year ago seekingalpha.com
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe,…
1 year ago globenewswire.com
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – –…
1 year ago globenewswire.com
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – –…
1 year ago businesswire.com
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc.,…
1 year ago globenewswire.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –
1 year ago businesswire.com
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago zacks.com
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
1 year ago globenewswire.com
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –
1 year ago zacks.com
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.
1 year ago businesswire.com
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago zacks.com
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is…
1 year ago prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024…
1 year ago prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning…
1 year ago benzinga.com
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.
1 year ago businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to…
1 year ago investopedia.com
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer…
1 year ago businesswire.com
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for…
1 year ago benzinga.com
Top 3 Health Care Stocks You May Want To Dump In February
Top 3 Health Care Stocks You May Want To Dump In February
-
1 year ago benzinga.com
Earnings Scheduled For February 20, 2025
Earnings Scheduled For February 20, 2025
1 year ago benzinga.com
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
1 year ago benzinga.com
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
1 year ago benzinga.com
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024
-
2 years ago benzinga.com
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.
-
2 years ago benzinga.com
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 years ago benzinga.com
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
-
4 years ago benzinga.com
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for…
-
4 years ago benzinga.com
41 Stocks Moving In Friday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
-
4 years ago benzinga.com
Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
-
4 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
4 years ago benzinga.com
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 721 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 596 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Monday morning saw 558 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 166 companies hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 342 companies made new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
During Thursday's morning session, 316 companies made new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
This morning 167 companies reached new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 322 companies hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
This morning 180 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
This morning 118 companies reached new 52-week highs.